< strong>▎WuXi Contex Content Team Editor

Today, Pfizer announced its second quarter 2022 financial results. During the conference call, the company’s executives highlighted recent advances in infectious diseases, metabolic diseases, and oncology. WuXi AppTec’s content team will share its highlights with readers. Reply to “Pfizer Financial Report” on WuXi AppTec’s WeChat account to download the full PPT file of the conference call. The latest research and development progress of the new crown vaccineWith the With the continuous mutation of the new coronavirus, Pfizer and BioNTech are also further developing preventive vaccines against the new coronavirus variants. Currently, the two companies have developed monovalent vaccines against Omicron BA.1 variants, Omicron BA.4/5 variants, and bivalent vaccines against Omicron BA.4/5. In mouse experiments, monovalent and bivalent vaccines against Omicron BA.4/5 as booster needles significantly improved the neutralization ability of animals against all Omicron variants.

Image Source: Pfizer official websiteCurrently, the company has launched a Phase 1/2 clinical trial to test the efficacy of a bivalent COVID-19 vaccine against wild-type and Omicron BA.2 variants, and is developing pan-COVID-19 A virus vaccine, with a proof-of-concept study planned to start in the second half of the year. mRNA influenza vaccine activates T cell responsesmRNA-based technology The 4-valent influenza vaccine is currently being tested in Phase 2 clinical trials. Preliminary data showed that in volunteers over the age of 65, the 4-valent influenza vaccine elicited CD4-positive and CD8-positive T cell responses against all 4 virus strains carried by the vaccine. Based on the positive T cell response and seroconversion data, Pfizer plans to conduct a Phase 3 clinical trial to further evaluate the efficacy of this vaccine.

▲4-valent influenza vaccine candidate elicits CD4-positive and CD8-positive T cell responses (Image source: Pfizer official website)

Potential “best-in-class” oral GLP-1 receptor agonists rapidly reduce blood sugar and body weight At present, a number of GLP-1 receptor agonists have been marketed to help control blood sugar in diabetic patients and help obese patients lose weight. However, these GLP-1 receptor agonists all need to be administered by injection, which brings unchanged medication to patients. The GLP-1 receptor agonist PF-07081532 being developed by Pfizer is an oral GLP-1 receptor agonist. Early clinical trial data show that once-daily oral administration of this drug in The investigational therapy significantly lowered blood sugar levels and reduced body weight by 5 kg in diabetic patients within 6 weeks.

Image source: Pfizer official website Bispecific antibody targeting BCMA achieves 64% objective response rateThe company’s elranatamab ( PF-06863135) is a bispecific antibody targeting B cell maturation antigen (BCMA). One end of it binds to BCMA, and the other end binds to the CD3 receptor on the surface of T cells, thereby activating T cells to kill cancer cells expressing BCMA. elranatamab achieved 64% confirmation in clinical trials for the treatment of relapsed/refractory multiple myeloma, new results reported at this year’s ASCO Annual MeetingObjective response rate, 35% of patients achieved strict complete remission or complete remission. Results from the pivotal clinical trial of this bispecific therapy are expected in the second half of this year.

Image source: Pfizer’s official websitePfizer expects up to 15 regulatory approvals, results from 14 pivotal clinical trials and 14 proof-of-concept studies in the next 18 months. The company also presented its second-quarter operations in the earnings report. Due to space limitations, this article will not introduce them one by one. You can download the complete PPT file of the conference call by replying to “Pfizer Financial Report” on WuXi AppTec’s WeChat account.

References:

[1] PFIZER REPORTS SECOND-QUARTER 2022 RESULTS. Retrieved July 28, 2022, from https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-PFE-Earnings-Release.pdf

[2] Second Quarter Earnings Teleconference. Retrieved July 28, 2022, from https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2 -2022-Earnings-Charts-FINAL.pdf

Disclaimer: WuXi AppTec content team focuses on global biomedical health research progress. This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec’s position, nor do they represent WuXi AppTec’s support or opposition to the views expressed in this article. This article is also not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Copyright note: This article is from WuXi AppTec content team, you are welcome to forward it to the circle of friends, declined Unauthorized reprinting by media or institutions to other platforms in any form. For reprint authorization, please reply to “Reprint” on the WeChat public account of “WuXi AppTec” for instructions on reprinting.

share, dotsLike, watching, focusing on global biomedical health innovation